title: Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.
authors.affiliation: Synertron, Inc., Madison, WI.
authors.forename: J D
authors.initials: JD
authors.lastname: Schiesel
authors.forename: M
authors.initials: M
authors.lastname: Carabasi
authors.forename: G
authors.initials: G
authors.lastname: Magill
authors.forename: E
authors.initials: E
authors.lastname: Casper
authors.forename: E
authors.initials: E
authors.lastname: Cheng
authors.forename: L
authors.initials: L
authors.lastname: Marks
authors.forename: J
authors.initials: J
authors.lastname: Feyzi
authors.forename: N J
authors.initials: NJ
authors.lastname: Clendeninn
authors.forename: R V
authors.initials: RV
authors.lastname: Smalley
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005493:Folic Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D005493:Folic Acid Antagonists; D011743:Pyrimidines; C024530:piritrexim